• In late May 2026, MannKind Corporation disclosed that the FDA has released it from a large, long-planned postmarketing lung cancer risk trial for Afrezza, leaving only a pediatric efficacy and safety requirement, while multiple new Afrezza and FUROSCIX data sets were presented at the American Diabetes Association’s 2026 Scientific Sessions.
• This shift meaningfully reduces Afrezza’s regulatory burden just as MannKind is pushing into pediatric use, including an ongoing INHALE-1st study in newly diagnosed youth with type 1 diabetes.
• We’ll now examine how the FDA’s decision to drop the large postmarketing lung cancer trial may reshape MannKind’s investment narrative and risk profile.

Uncover the next big thing with 23 elite penny stocks that balance risk and reward.

MannKind Investment Narrative Recap

To own MannKind today, you need to believe Afrezza and the Technosphere platform can justify the company’s concentrated bet on inhaled therapies despite ongoing adoption and competition challenges. The FDA’s decision to drop the large lung cancer trial meaningfully lightens Afrezza’s regulatory load, but the near term catalyst remains the pediatric Afrezza sBLA decision, while the biggest risk is still whether Afrezza can grow beyond a niche product.

The most relevant recent development here is the supplemental Afrezza BLA for children and adolescents, with an FDA decision scheduled for May 29, 2026. That pediatric ruling, together with the INHALE-1st study in newly diagnosed youth, directly ties into MannKind’s repositioning of Afrezza toward younger patients, where safety expectations are high and the lingering questions around pulmonary function and cancer risk still matter to how prescribers view the product.

Yet even with a lighter trial burden, investors should be aware that Afrezza’s long term pulmonary safety profile and prior lung cancer signal still...

MannKind's narrative projects $544.8 million revenue and $62.0 million earnings by 2029.

Uncover how MannKind's forecasts yield a $7.17 fair value, a 97% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts paint a harsher picture, expecting revenue of about US$447,000,000 in 2029 and only US$4,700,000 in earnings, which, combined with continued dependence on Tyvaso DPI and Afrezza, underlines how differently you can interpret the same Afrezza risk headlines and why new FDA decisions could shift these expectations.

Explore 3 other fair value estimates on MannKind - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your MannKind research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free MannKind research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate MannKind's overall financial health at a glance.

Looking For Alternative Opportunities?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Explore 28 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.
• The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.